Movement Alert|GlaxoSmithKline PLC rises 4.09% in Pre-Market Trading, collaboration with Alamar Biosciences highlights biomarker research push

Market Focus11-04

On November 4, GlaxoSmithKline PLC rose 4.09% in Pre-Market Trading, trading at $50.69 per share, with turnover of $2.2683 million.

The clearest fresh catalyst was Alamar Biosciences saying it will use its NULISA platform in a collaboration with GSK to study circulating protein signatures and disease progression, an update that points to continued external innovation activity around GSK’s research platform.

The announcement arrived after GSK’s late-October third-quarter report, in which revenue rose 4% to 8.89 billion pounds and the company reaffirmed full-year guidance for 3% to 5% revenue growth and 7% to 9% core EPS growth. That results backdrop was mixed, with specialty medicines showing double-digit growth while vaccines softened, and it was followed by cautious analyst actions including a Jefferies downgrade to Hold and an RBC target-price cut on the London listing.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment